Agilent Technologies (NYSE:A) Price Target Cut to $140.00 by Analysts at Barclays

Agilent Technologies (NYSE:A) had its price objective cut by Barclays from $150.00 to $140.00 in a report released on Tuesday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A has been the subject of a number of other reports. TD Cowen cut their target price on Agilent Technologies from $170.00 to $157.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Morgan Stanley cut their target price on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. UBS Group cut their target price on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Wells Fargo & Company dropped their price target on shares of Agilent Technologies from $175.00 to $165.00 and set an “overweight” rating on the stock in a research note on Thursday, February 26th. Finally, Evercore raised shares of Agilent Technologies from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $155.00 to $160.00 in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $160.53.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $120.40 on Tuesday. The company has a current ratio of 2.07, a quick ratio of 1.59 and a debt-to-equity ratio of 0.44. The stock has a 50 day simple moving average of $118.76 and a 200-day simple moving average of $134.11. The company has a market cap of $34.03 billion, a PE ratio of 26.58, a P/E/G ratio of 2.47 and a beta of 1.30. Agilent Technologies has a 12-month low of $99.12 and a 12-month high of $160.27.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.37 by ($0.01). The business had revenue of $1.80 billion for the quarter, compared to analyst estimates of $1.81 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, equities research analysts forecast that Agilent Technologies will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 22nd. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.255 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.8%. Agilent Technologies’s dividend payout ratio is currently 22.52%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Flynn Zito Capital Management LLC boosted its stake in Agilent Technologies by 3.2% in the 3rd quarter. Flynn Zito Capital Management LLC now owns 2,257 shares of the medical research company’s stock valued at $290,000 after buying an additional 69 shares in the last quarter. Forum Financial Management LP increased its holdings in shares of Agilent Technologies by 2.5% in the third quarter. Forum Financial Management LP now owns 2,921 shares of the medical research company’s stock valued at $375,000 after purchasing an additional 70 shares in the last quarter. Gabelli Funds LLC lifted its position in Agilent Technologies by 1.1% during the 3rd quarter. Gabelli Funds LLC now owns 6,620 shares of the medical research company’s stock valued at $850,000 after purchasing an additional 74 shares during the period. Fiduciary Trust Co grew its holdings in Agilent Technologies by 1.6% during the 3rd quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock worth $633,000 after acquiring an additional 77 shares during the period. Finally, NorthCrest Asset Manangement LLC grew its holdings in Agilent Technologies by 1.6% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 5,082 shares of the medical research company’s stock worth $726,000 after acquiring an additional 79 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.